Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Howmet Aerospace Inc (HWM) vs Eli Lilly And Co (LLY) Price & Performance

Howmet Aerospace IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Howmet Aerospace Inc vs Eli Lilly And Co — how do they compare? Howmet Aerospace Inc trades at $225.28 (market cap $88.76B), while Eli Lilly And Co trades at $1,174.03 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 11.7× Howmet Aerospace Inc's market cap, and Eli Lilly And Co pays the higher dividend (0.59%). Which is the better fit depends on your goals — on Pluang, investors hold Howmet Aerospace Inc for 35 Days and Eli Lilly And Co for 93 Days on average.

HWMLLY
Market Cap
$88.76B$1.04T
Volume
2,648,5163,064,878
Sector
IndustrialsHealth
52-Week High
$292.65$1.28K
52-Week Low
$184.09$799.57
Typical Hold Time
35 Days93 Days
Enterprise Value
$92.86B$1.09T
Dividend Yield
0.25%0.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Howmet Aerospace Inc

Howmet Aerospace (HWM) trades at $225.55, up 1.28% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue and net income are projected to grow in 2026, supported by robust demand in aerospace and defense. Analyst consensus is overwhelmingly bullish, with an 84% buy rating and a $328.10 price target, indicating significant upside potential from current levels.

The outlook for HWM is positive, driven by earnings growth and sector tailwinds, though technical indicators suggest near-term caution. Key risks include supply-chain pressures and competitive dynamics. Institutional interest remains strong, supporting the long-term investment case for shareholders focused on aerospace exposure.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HWM
0% Buy100% Sell
Avg holding period · 35 Days
LLY
22% Buy78% Sell
Avg holding period · 93 Days

Top news

Latest headlines on both assets

About Howmet Aerospace Inc

Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.

Read more on HWM →

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY →